Catatonia - Recognition, Lorazepam, and ECT

Key Points

• Catatonia is a psychomotor syndrome associated with mood, psychotic, neurologic, medical, and substance-related disorders.
• Mutism and immobility are not required; some patients present with severe purposeless excitement.
• Use a structured bedside examination such as the Bush-Francis scale to identify and track signs.
• A lorazepam challenge can support the diagnosis but a negative immediate response does not exclude catatonia.
• Lorazepam is first-line pharmacologic therapy for most cases.
• ECT should be used early for malignant, life-threatening, or benzodiazepine-resistant catatonia.
• Use antipsychotics cautiously during active catatonia, especially when malignant catatonia or NMS is possible.
• Prevent thrombosis, aspiration, malnutrition, dehydration, pressure injury, and contractures during immobility.

Algorithm

1. Identify catatonic motor and behavioral signs and quantify them with a structured scale when possible.
2. Evaluate for delirium, seizure, NMS, encephalitis, metabolic disease, infection, medication effects, and psychiatric causes.
3. Obtain targeted medical testing and EEG, neuroimaging, or CSF studies when the differential requires them.
4. Perform a lorazepam challenge when clinically appropriate and reassess objective signs.
5. Start scheduled benzodiazepine therapy and titrate to response while monitoring sedation and breathing.
6. Provide hydration, nutrition, VTE prevention, skin care, and aspiration precautions.
7. Escalate urgently to ECT for malignant catatonia, severe medical compromise, or inadequate benzodiazepine response.
8. Treat the underlying disorder and plan relapse prevention after the catatonic syndrome resolves.

Clinical Synopsis & Reasoning

Catatonia occurs in mood disorders, psychotic disorders, neurologic and autoimmune disease, metabolic illness, infection, medication states, and substance-related conditions. It is not synonymous with schizophrenia. Clinical features include stupor, mutism, staring, posturing, catalepsy, waxy flexibility, negativism, withdrawal, echolalia, echopraxia, stereotypy, mannerisms, grimacing, agitation that is not influenced by external stimuli, and autonomic abnormality. The Bush-Francis Catatonia Rating Scale can structure the examination and document response to treatment.

The differential is broad. Hypoactive delirium, nonconvulsive status epilepticus, severe parkinsonism, locked-in syndrome, akinetic mutism, neuroleptic malignant syndrome, serotonin syndrome, autoimmune encephalitis, and severe depression can overlap clinically. Catatonia and delirium can coexist, particularly in medically ill patients. Review recent antipsychotic exposure, withdrawal from benzodiazepines, seizures, infection, autoimmune symptoms, and abrupt behavioral change. A fluctuating level of attention alone should not lead clinicians to ignore classic catatonic motor signs.

A lorazepam challenge can support the diagnosis and predict benzodiazepine response. A common approach is 1 to 2 mg IV or IM, or an appropriate oral dose when parenteral administration is not feasible, followed by repeat examination after a short interval. A marked reduction in catatonic signs supports the diagnosis, although lack of an immediate response does not exclude it. Malignant catatonia is characterized by catatonia plus fever, severe autonomic instability, delirium, and potentially rigidity or elevated CK and requires emergency treatment.

Treatment Strategy & Disposition

Benzodiazepines, particularly lorazepam, are first-line treatment for most catatonia. After a positive challenge, scheduled lorazepam is titrated according to response and sedation, sometimes to substantially higher daily doses than those used for routine anxiety. Monitor respiratory status, falls, swallowing, hydration, and level of consciousness. Treat the underlying medical, neurologic, psychiatric, or substance-related cause simultaneously.

ECT is a first-line or early treatment for malignant catatonia and is indicated when catatonia is severe, life-threatening, or insufficiently responsive to benzodiazepines. Do not allow prolonged immobility, dehydration, refusal of nutrition, or autonomic instability to continue while repeatedly waiting for small medication changes. In severe cases, involve psychiatry and the ECT service urgently. Antipsychotics require caution during active catatonia, especially malignant presentations or when NMS is a concern, because dopamine blockade can worsen some cases. If antipsychotics are eventually needed for an underlying psychotic disorder, introduce them thoughtfully after catatonia improves and risk-benefit assessment is complete.

Prevent medical complications aggressively. Provide hydration and nutrition, aspiration precautions, pressure-injury prevention, bowel and bladder care, range-of-motion measures, and venous thromboembolism prophylaxis when indicated. Assess for rhabdomyolysis, renal injury, dehydration, and infection in prolonged immobility. Patients with excited catatonia may need a low-stimulation safe environment while definitive treatment is initiated.

Epidemiology / Risk Factors

• Catatonia occurs in psychiatric hospitals and general medical settings and is underrecognized when clinicians associate it only with schizophrenia.
• Mood disorders are among the most common psychiatric conditions associated with catatonia.
• Medical and neurologic causes are particularly important in first episodes, older adults, and patients with atypical features.
• Malignant catatonia is uncommon but carries substantial mortality without prompt treatment.

Investigations

Triggers and Associations

Pharmacology

Prognosis / Complications

• Many patients respond rapidly to lorazepam, especially when treatment is initiated early.
• ECT is highly effective in severe or medication-resistant catatonia.
• Delayed diagnosis increases risks of dehydration, infection, thrombosis, pressure injury, malnutrition, rhabdomyolysis, and death.
• Recurrence can occur if the underlying mood, psychotic, neurologic, or medical condition is not treated.

Patient Education / Counseling

• Explain to family that catatonia is a medical syndrome affecting movement and behavior, not simply unwillingness to speak or move.
• Recovery can be rapid after benzodiazepines or ECT, but the underlying cause still requires treatment.
• Family observations about baseline behavior and the timing of symptom onset can be diagnostically valuable.
• ECT is a standard evidence-based treatment for severe catatonia and may be lifesaving in malignant cases.
• After recovery, review medication changes and early warning signs that might signal recurrence.

Notes

The lorazepam challenge is clinically useful because it turns a static examination into a response test. Improvement in speech, eye contact, movement, posture, or cooperation after lorazepam can be striking. The response should be documented with the same objective signs assessed before treatment.

Malignant catatonia and neuroleptic malignant syndrome overlap. Both can include fever, rigidity, autonomic instability, and elevated CK. Recent dopamine antagonist exposure favors NMS, but the syndromes can be difficult to distinguish. In either case, avoid reflexively escalating antipsychotics while the diagnosis is uncertain.

The medical complications of catatonia are part of the disease burden. A patient who has not eaten, drunk, or moved for days may require a medical unit, IV fluids, electrolyte correction, nutritional support, anticoagulant prophylaxis, and pressure-injury prevention in addition to psychiatric treatment.

References

1. British Association for Psychopharmacology Evidence-Based Consensus Guidelines for the Management of Catatonia (2023) — Link
2. PubMed: Evidence-based consensus guidelines for the management of catatonia — Link
3. American Psychiatric Association ECT Resources — Link